Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?
Video navigation menu
- SGLT2i CVOTs in T2DM 0:51
- RCTs with SGLT2i in HF 2:37
- The DAPA-HF trial: outcomes and key messages 6:03
- Traffic jam expected for drug therapy in HFrEF 8:50
- Possible mechanisms of action of SGLT2i 10:30
This lecture by prof. Faiez Zannad was part of an accredited symposium "Expanding opportunities for SGLT2i in clinical cardiology" held during ESC 2019 in Paris, France.
Faiez Zannad is Professor of Therapeutics and Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy, France. He is also Director of the Clinical Investigation Centre (Inserm-CHU) in Nancy.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.